Staphylococcal aureus infections - Biotech, Pharma and Life Science Channel
Staphylococcal aureus infections represent an enormous burden to public health systems. Traditionally restricted to the hospital setting as nosocomial infections, highly virulent strains have recently emerged in outside healthcare settings. Together with the increasing resistance to many antibacterials in a wide variety of staphylococcal strains, development of vaccines or specific and potent therapies for staphylococcal diseases raised increasing interest . Finding a vaccine for staphylococci is not trivial, as protective immunity to staphylococcal infections does not appear to exist at a significant degree. Promising results from novel approaches based on the combination of systematically selected antigens have been reported.
Passive immunotherapy with monoclonal therapeutic antibodies against S.aureus is another means to approach specific therapy of staphylococcal. While antistaphylococcal purified polyclonal immunoglobulins are not recommended for prevention of staphylococcal infections in preterm or VLBW neonates, monoclonal antibodies are currently emerging and are in early development. Although not specific, bactericidal proteins and peptides with activity against S. aureus are in preclinical and clinical development.
The report includes a compilation of currently active projects in research and development of, antibodies, proteins, peptides and vaccines for prevention and treatment of Staphylococcus aureus infections. In addition, the report lists company-specific R&D pipelines of biologic and immune therapeutics of S. aureus infections. Competitor projects are listed in a tabular format providing information on:
News Articles
The new report* looks at respiratory syncytial virus (RSV), one of the most common causes of pediatric respiratory infections. Transmission is seasonal and the virus is spread through the air by an...
HHS-CCSC awards honor efforts to eliminate health care-associated infections
BOSTON, May 23, 2013 /PRNewswire/ -- The Critical Care Societies Collaborative (CCSC), in partnership with the U.S. Department of Health and Human Services (HHS), announces recipients in the 201...
Arsanis Nominates Preclinical Candidate for Staphylococcus aureus Program
Receives additional grant support to expand its infectious disease antibody pipeline Arsanis Biosciences GmbH, a biotechnology company developing anti-infective human m...
Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
MILFORD, Mass., May 23, 2013 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines for the treatment of viral infections, today announced...
Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced that following a planned interim safety review by its independent Data Safety Monitoring...
PASADENA, Calif., May 22, 2013 /PRNewswire/ -- The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conj...
Hygie is launching a new website!
BROSSARD, QC, May 22, 2013 /PRNewswire/ - Hygie® is launching a new website www.hygie.com . With our new modern, user-friendly site, hygiene solutions for healthcare and home settings are just...
Report by Johns Hopkins Cancer Center Suggests Neutral IV Connector is Safest
Fewer Infections and Less Clotting Associated with Neutral Fluid Displacement Connector, Says Presentation at Oncology Meeting Research on different types of IV connectors led...
Lehigh Valley Expands Fleet of Superbug-Slaying Robots
ALLENTOWN, Pa., May 21, 2013 /PRNewswire/ -- Lehigh Valley Health Network has announced the deployment of two additional TRU-D SmartUVCTM devices, adding to its existing arsenal of five...
Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
ROCKVILLE, Md., May 21, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, ann...
Companies
Aradigm Corporation and Grifols S.A.
Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of sever...
Cell Medica is a clinical stage cellular therapeutics company engaged in the development and delivery of cellular immunotherapy treatment strategies for infectious disease and can...
Around the world, medical professionals turn to Kimberly-Clark for a wide portfolio of solutions that improve the health, hygiene and well-being of their patients and staff. As pa...
Centegen, Inc., is a development-stage company focused on novel approaches to prevent and to treat infections caused by staphylococci.
PinPointe USA, Inc., located in Chico, California, develops and markets innovative laser-based devices for the treatment of infections by healthcare providers for patients worldwi...
Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatment...
Founded in 1994, IrriMax® Corporation develops and markets wound irrigation solutions using a patented, innovative delivery method that produces unmatched efficacy and safety....
Achaogen is a clinical-stage biopharmaceutical company focused on the discovery and development of antibiotics for the treatment of serious infections caused by multi-drug resista...
Colby is a privately held company based in Madison, WI and San Jose, CA. Colby is developing new oral small molecule signal transduction modulator drugs and immune modulator bioph...
Epidermolysis Bullosa (EB) is a rare genetic disorder characterized by the presence of extremely fragile skin and recurrent blister formation, resulting from minor mechanical fric...
Clinical Trials
Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection
The primary focus of the study is the evaluation of the safety of treatment with moxifloxacin in a pediatric population 3 months to
Safety and Acceptability of Carraguard™ Among HIV-Negative Couples in Thailand
The primary aims of the study were to assess the safety and acceptability of Carraguard applied vaginally prior to sexual intercourse for six months in both women and men; and to examine s...
Study Evaluating Emergency-Use Tigecycline in Subjects With Resistant Pathogens.
The purpose of this study is to provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations. The secondary objective is to evaluate the safety and effi...
Study of the Use of Coated Venous Catheters in the Critically Ill Child
This study should help determine to determine whether or not the use of an antibiotic coated catheter will significantly reduce the number of central line related bloodstream infections in...
Hospitalized patients at least 18 years of age, with Staphylococcus aureus bacteremia (SAB) will be enrolled into the study and receive one dose of Aurexis® intravenously on Study Day 1,...
Study Evaluating Vaccine in Adults With HIV
The purpose of this study is to learn whether the study vaccine and adjuvants (drugs that are used to help improve immune responses) have an acceptable safety profile in treating individua...
SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era
SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will b...
Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. I...
Organ Transplant Infection Prevention and Detection Project
Fungal infections are leading causes of morbidity and mortality in transplant recipients, yet comprehensive epidemiologic studies in this area are lacking. For this reason, the Centers for...
Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095
Therapeutic options for serious fungal infections are limited by intrinsic and acquired resistance to existing antifungal agents. For example, zygomycetes (such as Mucor spp.) are intrinsi...
PubMed Articles
The Cronobacter spp. are Gram-negative bacterial pathogens that can cause infections in all age groups, and have a high mortality rate in neonates due to necrotizing enterocolitis and meningitis. Rece...
Microsporum fulvum, an Ignored Pathogenic Dermatophyte: A New Clinical Isolation from Iran.
Misidentifying with Microsporum gypseum has for a long time been accounted for less prevalence of the geophilic species, Microsporum fulvum in human dermatophytosis. We describe a new case of infectio...
Trehalose does not affect the functions of human neutrophils in vitro.
PURPOSE: Trehalose, naturally occurring disaccharide, has been reported to prevent postoperative abdominal adhesions in animal models. We investigated whether trehalose affects the function of human p...
Application of Yeast Candida utilis to Ferment Eisenia bicyclis for Enhanced Antibacterial Effect.
In this study, fermentation broth of Eisenia bicyclis with Candia utilis YM-1 exhibited enhanced antimicrobial activity against methicillin-resistant Staphylococcus aureus (MRSA) and food-borne pathog...
Staphylococcus aureus and Enterococcus faecalis employ cyclic peptide-mediated quorum sensing (QS) systems, termed agr and fsr respectively, to regulate the expression of a series of virulence genes....
Pathogen-driven decision for implant retention in the management of infected total knee prostheses.
PURPOSE: In prosthetic joint infections (PJIs) of the knee, debridement with implant retention is associated with a high risk of recurrence. METHODS: A single-centre cohort study was performed with ex...
Partnership Concurrency and Coital Frequency.
National HIV prevalence estimates across sub-Saharan Africa range from less than 1 percent to over 25 percent. Recent research proposes several explanations for the observed variation, including prev...
End points in trials of treatments for skin infections--reply.
End points in trials of treatments for skin infections.
INTRODUCTION AND HYPOTHESIS: After SNM implantation the most significant complication that can occur is wound infection, which typically requires removal of all components. Such infections have been r...
Videos
Staph and MRSA
A brief description of staphylococcus aureus and MRSA.
Medical and Biotech [MESH] Definitions
Viridans Streptococci
A large heterogeneous group of mostly alpha-hemolytic streptococci. They colonize the respiratory tract at birth and generally have a low degree of pathogenicity. This group of species includes STREPTOCOCCUS MITIS; STREPTOCOCCUS MUTANS; STREPTOCOCCUS ORALIS; STREPTOCOCCUS SANGUIS; STREPTOCOCCUS SOBRINUS; and the STREPTOCOCCUS MILLERI GROUP. The latter are often beta-hemolytic and commonly produce invasive pyogenic infections including brain and abdominal abscesses.
Streptococcus Milleri Group
A subset of VIRIDANS STREPTOCOCCI, but the species in this group differ in their hemolytic pattern and diseases caused. These species are often beta-hemolytic and produce pyogenic infections.
Neisseria Meningitidis, Serogroup B
Strains of Neisseria meningitidis which are the most common ones causing infections or disease in infants. Serogroup B strains are isolated most frequently in sporadic cases, and are less common in outbreaks and epidemics.
Bifidobacteriales Infections
Infections with BACTERIA of the order Bifidobacteriales. This includes infections in the genera BIFIDOBACTERIUM and GARDNERELLA, in the family Bifidobacteriaceae.
Klebsiella Oxytoca
A species of gram-negative bacteria causing URINARY TRACT INFECTIONS and SEPTICEMIA.
